TruAlt Bioenergy Limited (TRUALT)
Investor Presentation
Investor Presentation - Q2FY27
- Consolidated total income grew 221% y-y; EBITDA up 532% y-y with 16.27% margin in H1 FY27
- Ethanol segment core with 65% dual-feed capacity; focus on capacity utilisation and feedstock cost
- CBG expansion progressing with phased commissioning; strategic partnerships with Sumitomo and GAIL
- SAF project in Andhra Pradesh advancing with ₹150 Cr grant; construction linked to blending roadmap
- Retail fuel network expanding to 13 outlets in Karnataka under Phase 1 rollout
- Financial discipline and working capital management prioritized for sustainable growth
- EBITDA margin improved to 15.91% standalone in H1 FY27 from 5.80% last year
- PAT turned positive with ₹94.27 Cr consolidated in H1 FY27 vs loss last year
- ROCE at 17.94%, Debt/Equity 0.55, Current Ratio 1.99 indicating healthy financials
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 TRUALT — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add TRUALT to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on TruAlt Bioenergy Limited
Important.
The summary above is generated automatically from TruAlt Bioenergy Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.